Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
0.3720
Dollar change
-0.0070
Percentage change
-1.85
%
Index- P/E- EPS (ttm)-12.59 Insider Own8.02% Shs Outstand11.74M Perf Week-4.32%
Market Cap4.37M Forward P/E- EPS next Y-0.11 Insider Trans4.32% Shs Float10.80M Perf Month-15.45%
Income-9.32M PEG- EPS next Q-1.00 Inst Own0.27% Short Float2.00% Perf Quarter-89.64%
Sales0.00M P/S- EPS this Y97.71% Inst Trans-13.11% Short Ratio0.14 Perf Half Y-93.92%
Book/sh0.78 P/B0.48 EPS next Y74.42% ROA-105.69% Short Interest0.22M Perf Year-98.87%
Cash/sh0.93 P/C0.40 EPS next 5Y- ROE-127.01% 52W Range0.34 - 36.25 Perf YTD-26.92%
Dividend Est.- P/FCF- EPS past 5Y-17.82% ROI-102.06% 52W High-98.97% Beta1.59
Dividend TTM- Quick Ratio6.03 Sales past 5Y0.00% Gross Margin- 52W Low8.17% ATR (14)0.05
Dividend Ex-Date- Current Ratio6.03 EPS Y/Y TTM-66.97% Oper. Margin0.00% RSI (14)32.33 Volatility13.58% 10.87%
Employees2 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom3.00 Target Price100.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q94.51% Payout- Rel Volume0.26 Prev Close0.38
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume1.55M Price0.37
SMA20-9.44% SMA50-18.21% SMA200-92.81% Trades Volume401,356 Change-1.85%
Feb-20-24 08:01AM
Feb-05-24 08:30AM
Jan-29-24 08:00AM
Dec-11-23 08:01AM
Nov-30-23 04:01PM
09:45AM Loading…
09:45AM
Nov-28-23 08:43AM
Nov-27-23 09:40PM
08:00AM
Nov-20-23 09:27AM
Nov-17-23 07:00AM
Nov-07-23 08:20AM
Nov-06-23 05:35PM
Sep-22-23 08:30AM
Sep-21-23 09:35AM
11:51AM Loading…
Sep-11-23 11:51AM
Sep-08-23 02:30PM
Aug-15-23 10:20AM
Aug-09-23 08:47AM
Jul-20-23 08:00AM
Jul-10-23 08:47AM
Jul-06-23 08:30AM
May-15-23 08:47AM
May-09-23 07:15AM
May-02-23 04:05PM
08:47AM
Apr-27-23 09:50PM
04:00PM
Apr-13-23 08:47AM
Apr-12-23 10:30AM
08:47AM Loading…
Apr-10-23 08:47AM
Mar-28-23 08:47AM
Feb-28-23 09:45AM
Feb-15-23 07:11AM
Feb-13-23 04:15PM
07:11AM
Feb-10-23 07:17AM
Feb-08-23 07:11AM
Feb-06-23 07:00AM
Jan-31-23 10:41AM
07:11AM
Jan-17-23 11:29AM
10:00AM
Dec-12-22 05:39AM
Dec-01-22 08:47AM
Nov-22-22 06:30AM
Oct-18-22 08:47AM
Oct-06-22 08:47AM
Sep-14-22 08:47AM
Jul-08-22 08:17AM
Jul-04-22 03:35PM
Jun-27-22 08:27AM
Jun-13-22 09:06AM
08:00AM
Jun-02-22 08:47AM
May-05-22 08:47AM
Mar-02-22 08:37AM
Feb-16-22 09:40AM
Feb-14-22 09:04AM
Feb-11-22 07:15AM
Feb-01-22 09:40AM
Jan-26-22 08:30AM
Jan-14-22 04:00PM
Jan-13-22 11:05AM
Jan-11-22 07:55PM
Tharimmune, Inc. is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death (IMCD) for drug resistant and devastating cancers. It also develops the Trident Artificial Intelligence (TAI) precision medicine platform which is used to identify biomarkers in its clinical programs to target a specific patient segment. The company was founded on March 28, 2017 and is headquartered in Bridgewater, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MILBY RANDYCEODec 15Buy0.5029,00014,587156,517Dec 18 10:04 AM
MILBY RANDYCEONov 30Buy1.0010,00010,000127,517Dec 04 04:15 PM